Skip to main
UTHR

United Therapeutics (UTHR) Stock Forecast & Price Target

United Therapeutics (UTHR) Analyst Ratings

Based on 11 analyst ratings
Buy
Strong Buy 36%
Buy 45%
Hold 18%
Sell 0%
Strong Sell 0%

Bulls say

United Therapeutics is well-positioned to become part of the standard of care for IPF patients as its recent TETON-1 data showed clinically meaningful preservation of FVC, improved patient symptoms and quality of life, and support for both mono and combination therapy use. With a significant opportunity in the IPF market and expected peak revenue of $5B from Tyvaso, the company has a strong financial outlook. Additionally, United is developing new delivery methods for its treatments to improve tolerability and is following a disciplined spending approach to support future launches and studies.

Bears say

United Therapeutics is currently generating stable but not exceptional revenues from its PAH franchise, and is highly dependent on the success of its treprostinil-based drugs. However, there are potential risks to these drugs achieving peak commercial revenue, such as market size, penetration rates, and generic erosion. Additionally, the company's operating expenses may not see significant decreases without additional business development. While the positive TETON-2 results for the use of Tyvaso in IPF increase the chances of success for TETON-1 and the FDA's new single pivotal trial policy may provide some protection, it is uncertain if these will be enough to significantly drive growth for the company in the near future.

United Therapeutics (UTHR) has been analyzed by 11 analysts, with a consensus rating of Buy. 36% of analysts recommend a Strong Buy, 45% recommend Buy, 18% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of United Therapeutics and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About United Therapeutics (UTHR) Forecast

Analysts have given United Therapeutics (UTHR) a Buy based on their latest research and market trends.

According to 11 analysts, United Therapeutics (UTHR) has a Buy consensus rating as of May 13, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $611.64, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $611.64, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

United Therapeutics (UTHR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.